ClinicalTrials.gg
CompletedNCT05814107Updated Nov 28, 2025

Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus

A Phase 1 interventional study of CT-996 and Placebo in Type 2 Diabetes and Overweight or Obesity, sponsored by Carmot Australia First Pty Ltd. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-28.

Sponsored by Carmot Australia First Pty Ltd (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies in Diabetes Mellitus, Type 2 by Hoffmann-La Roche — 7 open to participants now, 8 under way, 4 of them phase 3. Diabetes Mellitus, Type 2 · Hoffmann-La Roche.

Enrollment
45th of 73
94 · median 196
Started
2023
the only one that year
Phase 1
19 of 73
none open now
Registered
64th of 73
by date

Among the 73 studies in Diabetes Mellitus, Type 2 by Hoffmann-La Roche, this one is the 45th largest by enrollment, is the only one that started in 2023, is one of 19 in phase 1, and was the 64th registered.

Diabetes Mellitus, Type 2

10,392 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 73 studies in Diabetes Mellitus, Type 2 by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Diabetes Mellitus, Type 2 by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This study is designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of CT-996 in overweight/obese participants and participants with Type 2 Diabetes Mellitus (T2DM).

Read the detailed description

This is a multi-center, randomized, double-blind, placebo-controlled, dose escalation, first in human study designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of CT-996 when administered as single ascending doses (SAD) and multiple-ascending doses (MAD) in overweight/obese participants and as multiple doses (MD) in patients with T2DM.

03

Conditions studied

  • Type 2 Diabetes
  • Overweight or Obesity

Keywords

  • Type 2 Diabetes
  • Obesity
  • Overweight
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants 18-65 years old, inclusive
  • of 25 - 40, inclusive
  • Stable body weight for two months

Additional Inclusion Criterion for Part 3 (MD T2DM cohorts) only:

  • Participants in Part 3 should have a documented diagnosis of Type 2 Diabetes Mellitus (T2DM)
  • Participants in Part 3 should have (HbA1c) between 7.0% and 10.0%

Exclusion criteria

Exclusion Criteria:

  • History of significant medical conditions and
  • Uncontrollable hypertension
  • History of alcoholism or drug addiction within 1 year prior to Screening
  • Current or recent participation in an clinical trial
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
94 participants (actual)

Study arms

  • Experimental
    Part 1: CT-996 SAD Cohort 1

    Drug: CT-996

  • Experimental
    Part 1: CT-996 SAD Cohort 2

    Drug: CT-996

  • Experimental
    Part 1: CT-996 SAD Cohort 3, Then SAD Cohort 5

    During SAD Cohort 3, participants will be dosed under fasted conditions. During SAD Cohort 5, the same participants will receive the same dose under high-fat fed conditions.

    Drug: CT-996

  • Experimental
    Part 1: CT-996 SAD Cohort 4

    Drug: CT-996

  • Experimental
    Part 1: CT-996 SAD Cohort 6

    Drug: CT-996

  • Placebo comparator
    Part 1: Placebo SAD Cohort

    Drug: Placebo

  • Experimental
    Part 2: CT-996 MAD Cohort 1

    Drug: CT-996

  • Experimental
    Part 2: CT-996 MAD Cohort 2

    Drug: CT-996

  • Experimental
    Part 2: CT-996 MAD Cohort 3

    Drug: CT-996

  • Placebo comparator
    Part 2: Placebo MAD Cohort

    Drug: Placebo

  • Experimental
    Part 3: CT-996 MD T2DM Cohort 1

    Drug: CT-996

  • Experimental
    Part 3: CT-996 MD T2DM Cohort 2

    Drug: CT-996

  • Placebo comparator
    Part 3: Placebo MD T2DM Cohort

    Drug: Placebo

Interventions

  • DrugCT-996

    Capsule of CT-996

    Also known as: RO7795081, RG6652

  • DrugPlacebo

    Capsule of placebo matching CT-996.

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Time frame: From first study drug administration until last safety follow-up (up to 31 days [Part 1] or 58 days [Parts 2 and 3])

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of CT-996

    Time frame: At prespecified timepoints from Day 1 to Day 5 (Part 1) or Day 33 (Parts 2 and 3)

  2. Time to Maximum Observed Plasma Concentration (Tmax) of CT-996

    Time frame: At prespecified timepoints from Day 1 to Day 5 (Part 1) or Day 33 (Parts 2 and 3)

  3. Area Under the Concentration-Time Curve (AUC) from Time 0 to the Time of Last Measurable Concentration (AUC0-t) of CT-996

    Time frame: At prespecified timepoints from Day 1 to Day 5 (Part 1) or Day 33 (Parts 2 and 3)

  4. AUC from Time 0 Extrapolated to Infinity (AUC0-inf) of CT-996

    Time frame: At prespecified timepoints from Day 1 to Day 5 (Part 1) or Day 33 (Parts 2 and 3)

  5. Apparent Terminal Elimination Half-Life (t1/2) of CT-996

    Time frame: At prespecified timepoints from Day 1 to Day 5 (Part 1) or Day 33 (Parts 2 and 3)

  6. Part 1 Cohorts: Clearance (CL) of CT-996

    Time frame: At prespecified timepoints from Day 1 to Day 5

  7. Part 1 Cohorts: Volume of Distribution (V) of CT-996

    Time frame: At prespecified timepoints from Day 1 to Day 5

  8. Part 2 Cohorts: Minimum Observed Plasma Concentration (Cmin) of CT-996

    Time frame: At prespecified timepoints from Day 1 to Day 33

  9. Parts 2 and 3 Cohorts: Clearance Divided by the Bioavailable Fraction (CL/F) of CT-996

    Time frame: At prespecified timepoints from Day 1 to Day 33

  10. Parts 2 and 3 Cohorts: Volume of Distribution Divided by the Bioavailable Fraction (Vz/F) of CT-996

    Time frame: At prespecified timepoints from Day 1 to Day 33

  11. Part 1 SAD Cohorts 3 and 5: Food Effect of a High-Fat Meal on Cmax of CT-996

    Determine the effect of a high-fat meal on the PK of CT-996 following a single dose

    Time frame: At prespecified timepoints for up to 14 days

  12. Part 1 SAD Cohorts 3 and 5: Food Effect of a High-Fat Meal on AUC of CT-996

    Determine the effect of a high-fat meal on the PK of CT-996 following a single dose

    Time frame: At prespecified timepoints for up to 14 days

07

Study locations

2 sites
  • Nucleus Network Pty Ltd.
    Melbourne, 3004, Australia
  • Avant Santé Research Center S.A. de C.V.
    San Pedro Garza García, 66260, Mexico
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Nov 2025, 29 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 29 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2023
First posted
Apr 14, 2023
StartActual
May 9, 2023
Primary completionActual
Nov 7, 2025
CompletionActual
Nov 7, 2025
Last update
Nov 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05814107
Responsible party
Sponsor
First posted
Apr 14, 2023
Start date
May 9, 2023
Primary completion
Nov 7, 2025
Completion
Nov 7, 2025
Last update
Nov 28, 2025

Study contacts

Clinical Trials
study director · Carmot Therapeutics, Inc., a Member of the Roche Group

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tifeglipron

Start the discussion